The Journal of family practice
-
Pigmented macules on the patient's oral mucosa provided an important clue to the diagnosis.
-
At the end of the activity, participants will be able to: Identify the risks of kidney disease and their consequences in patients with T2DM. Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2DM and CKD. Become familiar with the mineralocorticoid receptor antagonist and endothelin receptor antagonist under latephase investigation.
-
After reading this review article on ADPKD, participants should be able to: Identify people at high risk for ADPKD. Conduct a diagnostic evaluation. Initiate evidence-based therapy to slow kidney progression and treat extra-renal manifestations.
-
Identify the benefits and limitations of statin therapy as a treatment option for lowering LDL-C. Intensify treatment in appropriate patients or refer for intensification. Describe the safety and efficacy of ezetimibe, bempedoic acid, PCSK9 inhibitors, LDL apheresis. Describe the safety and efficacy of medications in late-stage development or under review by the FDA for LDL-C reduction.
-
Apply evidence-based diagnostic guidelines for patients who have clinical features consistent with insomnia. Use evidence-based guidelines to develop comprehensive treatment plans that include cognitive-behavioral therapy, pharmacologic treatment, and combination therapies to achieve optimal outcomes Identify basic elements of cognitivebehavioral therapy for insomnia Differentiate among medications FDA-approved for treating insomnia by discussing mechanism of action, safety, efficacy, and use.